Written by The China Liquid Biopsy Market is witnessing significant development as demand grows for non-invasive cancer diagnostics and personalized healthcare solutions. MRFR estimates that the market will increase from USD 704 million in 2025 to USD 1,915 million by 2035, expanding at a CAGR of 10.53%. The market was estimated at USD 636.93 million in 2024.
Growing awareness of early cancer detection is creating additional demand for liquid biopsy technologies. Unlike conventional tissue biopsies, liquid biopsy can analyze biomarkers obtained from samples such as blood, providing opportunities for less-invasive disease assessment and monitoring. Advances in genomic technologies, including next-generation sequencing and digital PCR, are further strengthening analytical capabilities.
By application, cancer diagnosis holds the largest share, supported by the need for early and accurate detection. Treatment monitoring is emerging as an important growth area as healthcare providers seek ways to evaluate treatment responses. Blood remains the leading sample type, while urine-based testing is developing as researchers identify additional biomarkers and applications.
The competitive environment includes global diagnostic and biotechnology companies such as Guardant Health, Exact Sciences, Roche, Qiagen, and Thermo Fisher Scientific. Regulatory support and collaboration between research institutions and biotechnology companies are also contributing to innovation. Future opportunities include portable liquid biopsy devices, integrated testing solutions, and applications supporting personalized medicine.
Explore key developments shaping industry transformation:
Cd47 Targeting Therapeutics Market Volume
Autosomal Dominant Polycystic Kidney Disease Treatment Market Distribution